Clinical trials · Fresno, CA
Multiple myeloma clinical trials in Fresno
We’re tracking 3 recruiting multiple myeloma studies with a site in or near Fresno — including Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Fresno
- NCT06152575RecruitingPhase 3
Study of elranatamab for multiple myeloma that returned after other treatments
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
Fresno, CaliforniaAges 18 years+ - NCT05020236RecruitingPhase 3
Elranatamab with daratumumab for previously treated myeloma
This trial studies elranatamab (alone and combined with daratumumab) in people with multiple myeloma who have already received other treatments, including lenalidomide. It aims to see how well these medicines control the cancer and what side effects people experience.
Fresno, CaliforniaAges 18 years+ - NCT05552222RecruitingPhase 3
New treatment combo study for newly diagnosed multiple myeloma
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
Clovis, CaliforniaAges 18 years+
Hear when a new Multiple myeloma trial opens near Fresno, CA
We’ll email you when one opens near Fresno, CA — at most once a week, no account needed, unsubscribe anytime.
Multiple myeloma trials in other cities
Where these studies are running near Fresno
Institutions with a site for the recruiting multiple myeloma studies listed above.
- Clovis Community Medical Center · 2 studies
- Community Cancer Institute · 2 studies
- Community Regional Medical Center · 2 studies
- University of California San Francisco Fresno · 2 studies
- University of California, San Francisco - Fresno Center for Medical Education and Research
What taking part in a multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting multiple myeloma studies in California.
Common questions
- Are there multiple myeloma clinical trials near Fresno?
- Yes. We're currently tracking 3 recruiting multiple myeloma studies with a site near Fresno, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a multiple myeloma study near Fresno?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Fresno to take part?
- Not necessarily. These studies have a site near Fresno, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New multiple myeloma studies open near Fresno regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.